Thursday, February 24, 2011

VX-770 Shows Hope for CF Patients.

The Cystic Fibrosis Foundation and Vertex Pharmaceuticals announced today that VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis, showed promising results in a Phase 3 clinical trial.
Read the article using the link below.